Anti-CD152 Antibody – Pipeline Insights – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) 2026
The Anti-CD152 Antibody – Pipeline Insights – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) was valued at in and is anticipated to reach by , at a CAGR of xx% from 2026 to 2032.
The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Anti-CD152 Antibody – Pipeline Insights – 2018 Size, Share, Industry, Forecast and outlook (2024-2031).
This report delivers a comprehensive overview of the Anti-CD152 Antibody – Pipeline Insights – 2018 Size, Share, Industry, Forecast and outlook (2024-2031), with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Anti-CD152 Antibody – Pipeline Insights – 2018 Size, Share, Industry, Forecast and outlook (2024-2031). The Anti-CD152 Antibody – Pipeline Insights – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for –.
Anti-CD152 Antibody – Pipeline Insights – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) Scope:
Major Highlights
This report delivers a comprehensive overview of the Anti-CD152 Antibody – Pipeline Insights – 2018 Size, Share, Industry, Forecast and outlook (2024-2031), with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Anti-CD152 Antibody – Pipeline Insights – 2018 Size, Share, Industry, Forecast and outlook (2024-2031). The Anti-CD152 Antibody – Pipeline Insights – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for –.
This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Regional Analysis:
The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Anti-CD152 Antibody – Pipeline Insights – 2018 Size, Share, Industry, Forecast and outlook (2024-2031).
This report delivers a comprehensive overview of the Anti-CD152 Antibody – Pipeline Insights – 2018 Size, Share, Industry, Forecast and outlook (2024-2031), with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Anti-CD152 Antibody – Pipeline Insights – 2018 Size, Share, Industry, Forecast and outlook (2024-2031). The Anti-CD152 Antibody – Pipeline Insights – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for –.
Anti-CD152 Antibody – Pipeline Insights – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) Scope:
Major Highlights
This report delivers a comprehensive overview of the Anti-CD152 Antibody – Pipeline Insights – 2018 Size, Share, Industry, Forecast and outlook (2024-2031), with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Anti-CD152 Antibody – Pipeline Insights – 2018 Size, Share, Industry, Forecast and outlook (2024-2031). The Anti-CD152 Antibody – Pipeline Insights – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for –.
This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Regional Analysis:
- North America (U.S., Canada, Mexico)
- Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
- Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
- South America (Colombia, Brazil, Argentina, Rest of South America)
- Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
- Increase Your Customer Base by 3X using our Partner Identification tool
- Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.
- Identify high potential M&A targets based on synergies, market positioning and growth trajectory.
- Prioritize partners by strategic fit rather than general capability.
- Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.
- Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.
- White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.
- Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.
- Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.
- Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
ANTI-CD152 ANTIBODY
• Alternative names of anti-CD152 include Cytotoxic T-lymphocyte protein 4, Cytotoxic T-lymphocyte-associated antigen 4, CTLA-4, CD152, CTLA4. CD152 is a 33 kD member of the immunoglobulin superfamily. It is a cell surface glycoprotein expressed on activated T and B-lymphocytes.
• CD152 is same as CD28 in amino acid sequence, genomic organization, and structure and they share common B7 family counter-receptors (B7-1, B7-2). CD28 delivers a costimulatory signal in T cell activation, and CTLA-4 negatively regulates cell-mediated immune responses.
• CD152 plays a role in the induction and maintenance of immunological tolerance, as well as the development of protective immunity and thymocyte regulation. CTLA-4 is a group of inhibitory receptors that are being explored as cancer treatment targets through immune checkpoint blockade.
• Anti-CTLA4 (CD152) Antibody, clone 9H10 used in Western Blotting, Flow Cytometry, Immunoprecipitation that acts by enhancing T cell co-stimulation by blocking CTLA-4 interactions with the B7 co-receptors, favoring CD28 interactions.
• The mouse monoclonal Anti-CD152, clone BNI3, may be used for flow cytometric analysis of intracellular or surface CTLA-4 expression and is used for neutralization of CTLA-4 when expressed at the cell surface, thus used for the detection of CD152. AGEN1884, AGEN1181 are the anti-CTLA4 inhibitors by Agenus Inc, used in treating various types of cancer.
• Recently, CStone Pharmaceuticals announced its IND application for CS1002, an investigational CTLA-4 monoclonal antibody in 2018. Ipilimumab, an anti-CTLA4 antibody was approved by the U.S. FDA for the treatment of melanoma, a type of skin cancer.
• Its Clinical development was initiated by Medarex, which was later acquired by Bristol-Myers Squibb. ImmunOs Therapeutics AG is exploring novel family classes of therapeutics to stimulate the immune system and to increase the efficacy of checkpoint inhibitors (such as CTLA-4) and co-stimulatory agonists in multiple cancers (Pancreatic, Colon, Melanoma, Lymphoma, and Breast).
• The agreement of CBT pharmaceuticals gives exclusive worldwide development and commercialization rights to a novel, recombinant, human monoclonal antibody of Crown Bioscience, which targets a differentiated epitope on the CTLA-4 molecule.
• FPT155 (CD80-Fc), by five prime therapeutics, being studied for the treatment of solid tumors uses the binding interactions of soluble CD80 to: Directly engage CD28 to enhance its co-stimulatory activity, block CTLA-4 from competing for endogenous CD80, allowing CD28 signaling to prevail in T cell activation. ONC-392, a novel Anti CTLA 4 monoclonal antibody developed by OncoImmune Inc, for treating cancer is in the preclinical stage of drug development and recently announced that it has entered into an exclusive option and license agreement with Pfizer. Tremelimumab (CP-675206), by Pfizer, is used for treating Head and neck cancer; Liver cancer, etc. are in phase III trials of Drug Development.
• Xencor Inc, milestones for tumor microenvironment-targeting bispecific antibodies include Initiating Phase 1 trial to evaluate XmAb®20717, a PD-1 x CTLA-4 dual checkpoint inhibitor, Files IND for XmAb22841, a CTLA-4 x LAG-3 dual checkpoint inhibitor for the treatment of multiple oncology indications in 2018.
• The factors driving the global anti-CD152 antibody therapeutics market are high incidence rates of various types of cancers, the rise in investment in health care by the government and private organizations, increase in demand for minimally invasive surgeries, growing awareness about health, and early diagnosis of diseases.
• However, the rise in the cost of treatment, side effects associated with treatment, and lack of reimbursement policies in developing countries are likely to restrain the market.
• Alternative names of anti-CD152 include Cytotoxic T-lymphocyte protein 4, Cytotoxic T-lymphocyte-associated antigen 4, CTLA-4, CD152, CTLA4. CD152 is a 33 kD member of the immunoglobulin superfamily. It is a cell surface glycoprotein expressed on activated T and B-lymphocytes.
• CD152 is same as CD28 in amino acid sequence, genomic organization, and structure and they share common B7 family counter-receptors (B7-1, B7-2). CD28 delivers a costimulatory signal in T cell activation, and CTLA-4 negatively regulates cell-mediated immune responses.
• CD152 plays a role in the induction and maintenance of immunological tolerance, as well as the development of protective immunity and thymocyte regulation. CTLA-4 is a group of inhibitory receptors that are being explored as cancer treatment targets through immune checkpoint blockade.
• Anti-CTLA4 (CD152) Antibody, clone 9H10 used in Western Blotting, Flow Cytometry, Immunoprecipitation that acts by enhancing T cell co-stimulation by blocking CTLA-4 interactions with the B7 co-receptors, favoring CD28 interactions.
• The mouse monoclonal Anti-CD152, clone BNI3, may be used for flow cytometric analysis of intracellular or surface CTLA-4 expression and is used for neutralization of CTLA-4 when expressed at the cell surface, thus used for the detection of CD152. AGEN1884, AGEN1181 are the anti-CTLA4 inhibitors by Agenus Inc, used in treating various types of cancer.
• Recently, CStone Pharmaceuticals announced its IND application for CS1002, an investigational CTLA-4 monoclonal antibody in 2018. Ipilimumab, an anti-CTLA4 antibody was approved by the U.S. FDA for the treatment of melanoma, a type of skin cancer.
• Its Clinical development was initiated by Medarex, which was later acquired by Bristol-Myers Squibb. ImmunOs Therapeutics AG is exploring novel family classes of therapeutics to stimulate the immune system and to increase the efficacy of checkpoint inhibitors (such as CTLA-4) and co-stimulatory agonists in multiple cancers (Pancreatic, Colon, Melanoma, Lymphoma, and Breast).
• The agreement of CBT pharmaceuticals gives exclusive worldwide development and commercialization rights to a novel, recombinant, human monoclonal antibody of Crown Bioscience, which targets a differentiated epitope on the CTLA-4 molecule.
• FPT155 (CD80-Fc), by five prime therapeutics, being studied for the treatment of solid tumors uses the binding interactions of soluble CD80 to: Directly engage CD28 to enhance its co-stimulatory activity, block CTLA-4 from competing for endogenous CD80, allowing CD28 signaling to prevail in T cell activation. ONC-392, a novel Anti CTLA 4 monoclonal antibody developed by OncoImmune Inc, for treating cancer is in the preclinical stage of drug development and recently announced that it has entered into an exclusive option and license agreement with Pfizer. Tremelimumab (CP-675206), by Pfizer, is used for treating Head and neck cancer; Liver cancer, etc. are in phase III trials of Drug Development.
• Xencor Inc, milestones for tumor microenvironment-targeting bispecific antibodies include Initiating Phase 1 trial to evaluate XmAb®20717, a PD-1 x CTLA-4 dual checkpoint inhibitor, Files IND for XmAb22841, a CTLA-4 x LAG-3 dual checkpoint inhibitor for the treatment of multiple oncology indications in 2018.
• The factors driving the global anti-CD152 antibody therapeutics market are high incidence rates of various types of cancers, the rise in investment in health care by the government and private organizations, increase in demand for minimally invasive surgeries, growing awareness about health, and early diagnosis of diseases.
• However, the rise in the cost of treatment, side effects associated with treatment, and lack of reimbursement policies in developing countries are likely to restrain the market.
